Regeneron Pharmaceuticals Inc Regeneron (NASDAQ: REGN) And Sanofi’s Dupixent Accepted For Review By FDA Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) revealed on Thursday that FDA has awarded the authorization to Dupixent as an add-on cure for moderate-to-severe asthma.
Adamis Pharmaceuticals Corporation (ADMP) Adamis Pharmaceuticals (NASDAQ: ADMP) Submitted IND To FDA For Tempol Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has disclosed that it has submitted the Investigational New Drug (IND) application to FDA for Tempol. The purpose of this IND is to get authorization for the use of Tempol to cure the COVID-19 patients.
Adamis Pharmaceuticals Corporation (ADMP) FDA Rejects NDA For Adamis' (NASDAQ: ADMP) ZIMHI Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has announced Monday that it has got a Complete Response Letter (CRL) from FDA. The company disclosed that in CRL FDA declared that they need resubmission of NDA as the current application is not as per their priorities. Adamis